Meta AnalysisID 3848
棕榈酸帕利哌酮治疗精神分裂症的疗效和安全性：一项系统评价与Meta分析
CRD42013004713
The objective of this review is to compare the efficacy, safety, and level of adherence with paliperidone palmitate compared to any other available antipsychotic in the treatment of schizophrenia and schizophrenia spectr
Relationship Network
Interactive first-hop connections across herbs, ingredients, formulas, targets, diseases, symptoms, syndromes, evidence, and monographs.
Click a node to open it in a new tab
Ingredient: 1Meta-analysis: 1Links: 1
Arranging relationship network...
Record Fields
Scalar fields from the final meta_analysis record.
- Meta Analysis Id
- 3848
- Evidence Id
- 12406
- Core Evidence Id
- 12406
- Source Meta Analysis Id
- 3801
- Herb2 Meta Analysis Id
- HBMA003801
- Crd Id
- CRD42013004713
- Title
- Paliperidone palmitate efficacy and safety in the treatment of schizophrenia: a systematic review and meta-analysis
- Review Question
- The objective of this review is to compare the efficacy, safety, and level of adherence with paliperidone palmitate compared to any other available antipsychotic in the treatment of schizophrenia and schizophrenia spectrum disorders.
- Study Type Included
- Condition Being Studied
- Participant
- Animal
- Human Disease Modelled
- Intervention
- The long-acting injectable, paliperidone palmitate at any dose administered at either the deltoid or gluteal site. Both fixed dose and flexible dose designs will be included. Trials involving the intervention used alone or as part of combination therapy will be accepted provided the conjunctive agent is the same in the comparator group. Minimum duration of therapy of four weeks must be met. Trials using oral paliperidone as the intervention will be excluded. Supplemental oral doses during initiation and dosage changes will be allowed although we won’t expect to see supplementation in the PP arm.
- Comparator Control
- We will only accept trials using an active comparator because the efficacy of paliperidone palmitate versus placebo has been established in a number of randomized controlled trials (Kramer 2009, Gopal 2010, Hough 2010, Nasrallah 2010, Pandina 2010) and other comprehensive systematic reviews (Citrome 2010, Gopal 2011, Nussbaum 2012). We aim to address the patient-specific question clinicians face when choosing a therapy, clinically, placebo would not be an option. In the present systematic review we wish to discern whether paliperidone palmitate offers an efficacy, safety or adherence benefit over current standard care, which would involve antipsychotic pharmacotherapy. Any antipsychotic available in North America would be an acceptable comparator. The comparator may be given at any dose (both fixed dose and flexible dose designs will be included), and by any route (oral, sublingual, intravenous, intramuscular including by long-acting injection (LAI)). We plan to analyze short-acting comparators and LAI agents separately. The comparator may be used alone or as part of a combination therapy provided the conjunctive agent is the same in the intervention group. Supplemental oral doses during initiation and dosage changes will be allowed.
- Main Outcome
- Outcome Measure
- Additional Outcome
- Study Method
- Intervention, Meta-analysis
- Keyword
- Antipsychotic Agents; Humans; Palmitates; Schizophrenia
- Contact
- Organisational Affiliation
- Funding Source
- Other Selection Criteria
- Final Publication
- Same Topic Review
- Published Protocol
- Review Type
- Language
- English
- Country
- Canada
- Review Stage
- First Submission Date
- Registration Date
- 2013-05-31
- Anticipated Start Date
- Anticipated Completion Date
- Title Cn
- 棕榈酸帕利哌酮治疗精神分裂症的疗效和安全性：一项系统评价与Meta分析
- Title En
- Paliperidone palmitate efficacy and safety in the treatment of schizophrenia: a systematic review and meta-analysis
- Bilingual Status
- complete